United States

Next Bio-Research Services begins operations

Wednesday, November 11, 2015

Next Bio-Research Services has officially began operations in the Ironbridge Medical Park in Chester, Va. The company continues a 23-year history of providing comprehensive integrated project support to investigators in the biotech and pharmaceutical sectors and in providing medical testing services to physicians using state-of-the-art platforms.

[Read More]

NIH awards City of Hope $2.2M grant

Thursday, November 5, 2015

The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) has awarded a $2.2 million grant to help City of Hope researchers explore the underlying mechanisms of graft-versus-host disease, the leading cause of long-term sickness and death following transplantation of bone marrow cells from a donor. The grant, awarded to Defu Zeng, M.D., a professor of diabetes immunology and hematopoietic cell transplantation at the Beckman Research Institute of City of Hope, will be used by researchers to study the interactions of immune cells known as T cells and B cells during the development of GVHD.

[Read More]

FDA approves Imlygic

Thursday, November 5, 2015

Amgen has announced that the FDA has approved the Biologics License Application for Imlygic (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery. Imlygic has not been shown to improve overall survival or have an effect on visceral metastases. Imlygic is the first oncolytic viral therapy approved by the FDA based on therapeutic benefit demonstrated in a pivotal study.

[Read More]